Lymphoma / Leukemia News From Medical News TodayLatest Lymphoma / Leukemia News From Medical News Today.Intrabone Administration Of Unrelated Cord-Blood Cells Is Successful In Enabling More Patients With Acute Leukaemia To Undergo Transplantation- August 9, 2008 Intrabone administration of unrelated umbilical-cord-blood cells overcomes the problem of graft failure seen with intravenous administration and is associated with a low incidence of graft-versus-host disease, making the technique potentially useful in a large number of adult patients with acute leukaemia, according to findings from a phase III study, published early Online and in the September edition of The Lancet Oncology.http://www.medicalnewstoday.com/articles/117780.php GlaxoSmithKline And Genmab Announce Positive Top-line Results In Ofatumumab Chronic Lymphocytic Leukaemia Pivotal Study- August 9, 2008 GlaxoSmithKline (LSE and NYSE: GSK) and Genmab AS (OMX: GEN) announced today positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20) in two difficult to treat groups of patients with chronic lymphocytic leukaemia (CLL). At the interim analysis, the study met the primary endpoint in both populations and the results from the secondary endpoints also support the primary endpoint.http://www.medicalnewstoday.com/articles/117771.php Why Gene Therapy Caused Leukemia In Some "Boy In The Bubble Syndrome" Patients- August 8, 2008 Severe combined immunodeficiency (SCID), sometimes called 'Boy in the bubble syndrome', is a genetic disorder in which the patient lacks most types of immune cell. Almost 10 years ago, two independent groups (one in London, United Kingdom, and one in Paris, France) used gene therapy to treat a few infants with the most common form of SCID, SCID-X1, which is caused by mutations in the IL2RG gene.http://www.medicalnewstoday.com/articles/117654.php InNexus Biotechnology Announces Launch Of Large Scale Primate Study Of DXL625- August 8, 2008 InNexus Biotechnology Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF) (http:www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announced that it has launched a large scale primate study of DXL625 (CD20), the company's lead program.http://www.medicalnewstoday.com/articles/117621.php Early Warning Of Leukaemia Or False Alarm- August 8, 2008 Researchers have for the first time shown that many people have cells in their blood which appear identical to leukaemia and yet the risk of developing the disease for most is virtually zero.http://www.medicalnewstoday.com/articles/117592.php Leukemia Journal Publishes Results From Darinaparsin Study- August 6, 2008 ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 on line advance publication issue of Leukemia, a Nature publication. The article, titled "A novel arsenical has antitumor activity toward As2O3-resistant and MRP1ABCC1- overexpressing cell lines," was led by Wilson Miller, M.D., Ph.D., Professor, Medicine and Oncology, McGill University-Jewish General Hospital in Montreal, Canada.http://www.medicalnewstoday.com/articles/117348.php Fudan-Cinpathogen Study Shows Chronic Lymphoid Neoplasms Are More Common In Shanghai Than Thought- August 5, 2008 A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China published online in the International Journal of Hematology shows significant differences in frequency of subtypes of lymphoma and other lymphoid neoplasms between China and the West.http://www.medicalnewstoday.com/articles/117180.php Some Types Of Leukemia Are Addicted To Notch Proteins- August 4, 2008 The leukemic cells in a large proportion of individuals with a form of leukemia known as T-ALL have mutations in the NOTCH1 gene. These mutations lead to the generation of Notch1 proteins that have increased activity, however, it is not known whether they have sufficient increased activity to actually initiate the disease.http://www.medicalnewstoday.com/articles/117045.php MabThera Filed In The EU For Treatment Of Most Common Leukaemia In Adults- August 1, 2008 Submission Based on Phase III Study Showing Superior Results for MabThera in Chronic Lymphocytic Leukaemia (CLL) When Added to Standard Chemotherapy Today, Roche submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for the use of its biotechnology drug MabThera (rituximab) as first-line treatment of chronic lymphocytic leukaemia, the most common form of adult leukaemia.http://www.medicalnewstoday.com/articles/116925.php Lymphoma Research Foundation Announces Its 2008 Research Grant Recipients- August 1, 2008 As part of its ongoing effort to find a cure for lymphoma, the Lymphoma Research Foundation (LRF) proudly announces the 2008 Research Grant Recipients of its Post-Doctoral Fellowships and Clinical Investigator Career Development Awards, LRF's two cornerstone research programs. The two-year Post-Doctoral Fellowships help attract the nation's best scientific talent to careers in lymphoma and allows them to pursue promising research projects under the guidance of a mentor.http://www.medicalnewstoday.com/articles/116860.php |